Royalty Report: Ophthalmological, Medical, Device – Collection: 27481

License Grant

In 1993, the Company obtained a license for a patent on a photoscreening device; specialized Polaroid-type instant film camera designed to detect conditions that lead to amblyopia (lazy eye) and other eye disorders from the Licensor, an individual.

License Property

The MTI Photoscreener(TM) is designed to take a photograph of a child's eye and detect factors which can lead to amblyopia (lazy eye), including strabismus (misalignment of the eye), cataracts (cloudy lenses), and asymmetric or other abnormal refractive errors, including myopia (nearsightedness), hyperopia (farsightedness), and astigmatism.

The MTI Photoscreener(TM) consists of a single flash placed close to the center of the lens of the subject's eye to accentuate the red eye appearance of a subject for diagnostic purposes. By placing the flash close to the lens aperture, abnormal refractive errors of the eye are imaged as white crescents in the red eye reflex, a process scientifically known as photo refraction.

Field of Use

PhotoScreener is a specialized Polaroid-type instant film camera designed to detect conditions that lead to amblyopia ('lazy eye') and other eye disorders.

License Grant

The license was granted for use on the exclusive territory to the Swiss Licensee by the Russian Licensor.

License Property

Licenser possesses the 'Technology for Producing Collagen-Based Cross-Linked Drain', and the Licensiate wants to acquired the license on this technology. Technology of production intraocular lenses from collagen co-polimers.   Artificial eye lenses, which are implantated through small sizes, are most perspective.  Several requirements are produced to artificial eye lenses like elasticity, biocompatibility, low specific density and high solidity on rupture.  Artificial eye lenses from collagen co-polimers corresponds to these principles.

Technology of production intraocular lenses from collagen co-polimers Nowadays, intraocular correction is one of the basic medical treatment method of vision body disease.
Artificial eye linses are used not only when cataract, but also for removal of refraction anomalies.
Artificial eye lenses, which are implantated through small sizes, are most perspective. Several requirements are produced to artificial eye lenses like elasticity, biocompatibility, low specific density and high solidity on rupture. Artificial eye lenses from collagen co-polimers corresponds to these principles.
Highest elasticity, hight solidity on rupture are the main quality of these products. It allows to make implantation as tool-making method of injection also.
Lenses, which are maked an special technology, passed experimental and hospital tests successfully and inculcated in wide surgical practice as in Eye Microsurgery Intersectoral Research and Technology Complex so in the other Russian and CIS hospitals.

US patent N 6.286.829 (Russion application N 4745668) 'Biocompatible polymer material and a process for producing same'
USA patent N 5258025 (Russian application N 4881670) 'correctional intraocular lens'

License Grant

The Company has license agreements with an undisclosed former director wherein the Company has acquired rights to develop and commercialize certain research technologies.

The sale and assignment of Lotemax and Alrex.

License Property

Lotemax and Alrex are the trade names of drug products in the form of eye drop suspensions in which the active compound is loteprednol etabonate ('LE').

Lotemax is a topical, site-specific steroid that is used to treat steroid responsive inflammatory eye conditions. The prescription eye drop is also used for post-operative eye inflammations such as experienced following cataract surgery. The novel chemical structure of Lotemax allows it to be predictably transformed by enzymes in the eye to an inactive metabolite, thereby increasing its safety profile.

Alrex is a specially developed formula of loteprednol etabonate that is used in the treatment of ophthalmic allergies. Alrex is indicated for the treatment of seasonal allergic conjunctivitis, an inflammation of the eye usually caused by pollens. Seasonal allergic conjunctivitis produces itching, tearing, redness and swelling in the conjunctiva, the membrane that covers the inside of the eyelid and the white part of the eye.

License Grant

Licensor grants to Licensee an exclusive, worldwide, license, with the right to grant sublicenses, under Licensor Patents and Know-how to make, have made, use, import, offer for sale and sell the Catarex Products in the Licensee Field.

License Property

Licensor has developed a proprietary surgical instrument system designed to improve the removal of human cataracts, which instrument is generally referred to as Catarex-TM.

Catarex removes the lens nucleus and cortex in a single step through a small incision in the eye while leaving the lens capsule functionally intact.

Field of Use

Licensee Field means all applications of Catarex Products for human ophthalmic surgery.

License Grant

The Canadian Company has acquired an exclusive license to a patented technology that takes the application of fiber-optic, OMA based instrumentation as an in vivo diagnostic tool for the human ocular lens.

Field of Use

OMA based instrumentation as an in vivo diagnostic tool for the human ocular lens.

The Company is a medical device company focused on the marketing and development of ophthalmic surgery products for use in the laser eye surgery and cataract surgery markets.